Clinical trial · Interventional

Precision Cancer Therapy in Rare Cancers

The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers

NCT06119789CI-TRIAL-00087692MATRIX-RarerecruitingPhase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Rare Malignant Neoplasm	Rare Childhood Malignant Neoplasm	ALIAS	0.90

Interventions

Interventions (3)

Intervention	Type	Mapped drug	Match
Dabrafenib	Drug	Dabrafenib	ALIAS
Imatinib	Drug	Imatinib	ALIAS
Trametinib	Drug	Trametinib	ALIAS

Design

Arms and outcomes

Arms (1)

type
EXPERIMENTAL
label
treatment according to genetic alterations
description
treatment according to genetic alterations
interventionNames
1. Drug: Imatinib
2. Drug: Trametinib
3. Drug: Dabrafenib

Primary outcomes (1)

measure
Radiological response evaluation at 16 weeks of treatment
timeFrame
16 weeks
description
Standard radiological response evaluation, like RECIST criteria.

Secondary outcomes (1)

measure
Molecular analyses predicting responses
timeFrame
2 years

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 16 Years
Maximum age: 99 Years

Show eligibility criteria text

Inclusion Criteria:

* ECOG 0-2,
* identified biomarker,
* reasonable biochemistry

Exclusion Criteria:

* ECOG 3-5
* serious other diseases

References

Publications (0)

Data not yet available

No reference posted for this study.

Registry

Dates and enrollment

Start: Mar 20, 2025
Primary completion: Nov 30, 2033
Completion: Aug 1, 2036
First posted: Nov 7, 2023
Last update posted: Mar 26, 2025
Enrollment: 96 (estimated)
Lead sponsor: Oslo University Hospital OTHER
Collaborators: Helse Stavanger HF; University Hospital of North Norway; StOlavs Hospital; Nordlandssykehuset HF; Helse Nord-Trøndelag HF; Sorlandet Hospital HF; Møre og Romsdal Hospital Trust; The Hospital of Vestfold; Helse Fonna; Haukeland University Hospital; Sykehuset Ostfold; Helse Forde; Sykehuset Innlandet HF

Data updated 22 days agoSource updated Mar 26, 2025source: clinicaltrials

Locations

Locations by country (1)

Country	Sites	Recruiting
Norway	1	1

Trial listing is informational. Eligibility is decided by the study team; contact information is on ClinicalTrials.gov.